Differential diagnosis of hepatic injury mainly includes veno-occlusive disease (VOD), acute graft-versus-host disease (aGVHD) of the liver, infections and toxic drug Plasminogen activator inhibitor 1 (PAI-1) and aminopropeptide of type III procollagen (PIIINP) have been effects. 1 Owing to different therapeutic consequences, accurate diagnosis is essential and the identification of a described as markers of hepatic veno-occlusive disease (VOD) after bone marrow transplantation (BMT). We marker would be helpful. Laboratory parameters such as plasminogen activator determined these parameters in two patients undergoing BMT and subsequent liver transplantation due to inhibitor 1 (PAI-1; 2,3 ) and the aminopropeptide of type III procollagen (PIIINP; [4] [5] [6] ) have been reported to be elevated VOD. Previously normal PAI-1 levels (maximum 30.0 ng/ml in patient 1, 23.7 ng/ml in patient 2) were elevated and possibly useful in diagnosing VOD. We determined these parameters in two bone marrow transplant recipients for the first time in both patients at the time of clinically diagnosed VOD on days 40 and 20, respectively (patient who developed VOD and underwent subsequent liver transplantation. 1: 317.5 ng/ml; patient 2: 317.2 ng/ml). Levels remained elevated until liver transplantation was performed on days 79 and 41, respectively. Baseline levels (day −8) of aminopropeptide of type III collagen (patient 1: 4.44
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Patients and methods g/l; patient 2: 8.1 g/l) peaked at the time of BMT in both patients (155.0 g/l and 108.3 g/l). After an intermittent decrease at the time of discharge on day Case 1 32, a second elevation was observed in patient 1 when she was readmitted and presented with typical signs of A 39-year-old patient with acute myeloid leukemia was transplanted from her HLA-identical brother after con-VOD on day 40. In patient 2, PIIINP levels remained high until VOD was diagnosed (day 20) and liver transditioning with busulfan (16 mg/kg over 4 days) and cyclophosphamide (200 mg/kg over 4 days) in April 1995. The plantation was performed. After liver transplantation, PAI-1 levels normalized in both patients and PIIINP patient received low-dose heparin (100 U/kg/day) as VOD prophylaxis starting on day −8. After an uncomplicated levels declined. Both patients died due to infectious complications and multiorgan failure on days 141 and 101, course the patient was discharged on day 32. On day 40 she was readmitted to hospital with hyperbilirubinemia (74.8 respectively. Whereas the early rise of PIIINP did not correlate with the clinical onset of VOD, the results mmol/l), ascites, right upper quadrant pain, hepatomegaly, elevation of liver enzymes, fever and impaired coagulation. emphasise the relevance of PAI-1 for diagnosing VOD. Keywords: veno-occlusive disease; bone marrow trans-
The bilirubin level continued to rise. Transjugular liver biopsy was performed on day 47. Unfortunately insufficient plantation; liver transplantation; plasminogen activator inhibitor 1 (PAI-1); aminopropeptide of type III collagen material was obtained and the patient developed an intrahepatic hematoma precluding thrombolytic therapy. Treatment with PGE 2 (days 44-46 and 48-74) led to an improvement in the right upper quadrant pain and a Liver damage represents a key event in the most important decrease in liver enzymes, but the bilirubin continued to life-threatening complications following bone marrow rise. transplantation. In view of the growing numbers of highOn day 70, percutaneous liver biopsy confirmed the diagdose chemotherapy regimens and consecutive stem cell nosis of VOD. Liver transplantation was performed on day transplantations, an increasing rate of hepatic complications 79, when the bilirubin level was 1230.8 mmol/l. Histology can be expected.
of the explanted organ confirmed the diagnosis of massive VOD. After improvement of liver function the patient developed pulmonary aspergillosis on day 105, pseudo-
Case 2
A 47-year-old patient with chronic myeloid leukemia was transplanted from his HLA-identical sister after conditioning with busulfan (16 mg/kg over 4 days) and cyclophosphamide (200 mg/kg over 4 days) in October 1995. This patient also received low-dose heparin (100 U/kg/day) as VOD prophylaxis, beginning on day −8. The bilirubin level began to rise during the third week following BMT and the patient developed painful hepatomegaly and ascites. The diagnosis of VOD was confirmed by a percutaneous biopsy and thrombolytic therapy was initiated. He received 10 mg rtPA on days 20, 21, 23 and 24, without effect. After a further decline in hepatic function, liver transplantation was performed on day 41 when the bilirubin had reached a peak improved, anuria persisted. Additionally, the bone marrow was found to be hypoplastic and the patient continued to suffer from pancytopenia even after a second infusion of peripheral blood stem cells from his marrow donor on day 60. On day 95, another laparotomy was performed due to bile duct fistula. Over the ensuing days the patient developed progressive liver failure and died on day 101 after bone marrow transplantation. Blood samples (3.8% sodium citrate 9:1) were collected in a standardized manner during the morning at different time-points from day −8 (before BMT) to day 136 and 98, respectively.
PAI-1 was measured by an enzyme immunoassay (PAI-1 Asserachrom, Boehringer Mannheim, Germany; normal range range 4-43 ng/ml). The N-terminal propeptide for type III procollagen was determined by a radioimmuno- pressure liquid chromatography as described earlier. 7 Busulfan concentrations were determined before the start of conditioning treatment and subsequently every 6 h (days range in both patients. In patient 1, another late peak was 1-4) before each oral busulfan application. Reference observed on day 129 when she suffered from septic shock. values for busulfan trough concentrations were obtained by
In patient 2, PAI-1 remained elevated during the first week prospective analysis of 30 patients in whom VOD was not after liver transplantation when he suffered from a diagnosed in the follow-up evaluation after conditioning staphylococcal sepsis. The level returned to the normal treatment.
range after treatment of the sepsis episode. Baseline levels (day −8) of PIIINP (patient 1: 4.44 g/l; patient 2: 8.1 g/l) peaked on day 0 in both patients (155.0 Results g/l and 108.3 g/l). In patient 1 (Figure 1 ) after an intermittent decrease at the time of discharge (10.7 g/l on day 32), a second elevation was observed when she was readNormal PAI-1 levels were detected before VOD developed in both patients, reaching a maximum of 27.1 ng/ml in mitted and presented with typical signs of VOD on day 40 (68.8 g/l). patient 1 (Figure 1 ) and 23.7 ng/ml (Figure 2 ) in patient 2. At the exact time when patients presented with typical cliniIn patient 2 (Figure 2 ), PIIINP levels remained high, ranging from 82.0 g/l to 98.5 g/l between days 7 and cal signs of VOD and bilirubin levels exceeded 34 mmol/l for the first time, a marked increase of PAI-1 was noticed.
21 when VOD was diagnosed and from 76.7 g/l to 90.2 g/l between days 21 and 41, until liver transplantation This reached 317.5 ng/ml in patient 1 (day 47) and 317.2 ng/ml in patient 2 (day 21). Whereas a further increase was was performed. Following liver transplantation PIIINP levels declined in measured in patient 1 (Figure 1 ) until liver transplantation was performed (547.6 ng/ml on day 79) PAI-1 levels both patients. Unfortunately, steady state busulfan concentrations regressed but were still remarkedly elevated in patient 2 (166.3 ng/ml on day 39) at the time of liver transplantation.
(mean ± standard deviation) were only determined in patient 1. Mean busulfan trough concentrations during conAfter liver transplantation, PAI-1 levels fell to the normal ditioning were 741 ± 172 ng/ml between day 1 and 4 and PAI-1 after liver transplantation in both patients. In patient 1, PAI-1 normalized shortly after liver transplantation therefore exceeded those in 30 comparable BMT patients without VOD, where concentrations of 341 ± 50 ng/ml (Figure 1 ), but a late peak was observed on day 129 when the patient suffered from septic shock. On the other hand, were measured.
PAI-1 levels remained elevated for 1 week after liver transplantation, when patient 2 suffered from a severe staphylococcal sepsis, but subsequently normalized after treatment Discussion of sepsis. The N-terminal propeptide of type III collagen, which is The mortality from severe VOD is 98%. 8 Although the pathophysiology is far from clear there is evidence that released when type III collagen is synthesized, has been described as a useful marker for VOD in children 4,5 and damage to the endothelium of liver sinusoids and terminal hepatic venules triggers an activation of the coagulation adults 6 undergoing bone marrow transplantation. PIIINP levels in our patients were significantly elevated after consystem with consecutive obstruction of small intrahepatic veins, zone 3 hepatocyte necrosis and sinusoidal fibrosis. 9 ditioning as compared to baseline values. This is in agreement with data from Rio et al, 6 who described an elevation Since thrombolytic therapy with rtPA represents a promising therapy which can lead to a fast resolution of sympof PIIINP as early as day 0 in patients developing VOD. Nevertheless, the delay between the first rise of PIIINP toms, 10, 11 confirmation of the diagnosis and differentiation from other causes of hepatic injury -mainly acute graftand clinical onset of symptoms on days 20 and 40, respectively, casts doubt as to its usefulness as a marker of VOD. versus-host disease and infectious complications -is essential. Diagnosis can be confirmed most reliably by liver
We hypothesize that the first increment of PIIINP in our patients was due to hepatic toxicity resulting in endothelial biopsy, which, however, is associated with a serious risk of bleeding and which enhances the probability of cell disruption and a reduced clearance rate, as discussed earlier. 4 Damage to the endothelium may at least partly hemorrhagic complications if thrombolytic therapy is indicated. Therefore, laboratory markers are urgently needed.
have been provoked by significantly elevated busulfan levels in these patients as compared to patients without VOD. We have previously described PAI-1, which is synthesized and released by the endothelium, as a marker of hepOn the other hand, it can be speculated that enhanced type III collagen synthesis, as indicated by an elevation of atic VOD.
2,3 Whereas tPA levels remained unchanged during the course of BMT, PAI-1 was notably elevated in PIIINP, may be a predisposing factor for VOD. Additional factors such as the coincident elevation of PAI-1 with con-VOD patients clearly indicating hypofibrinolysis in this subgroup. The present results confirm this hypothesis since secutive hypofibrinolysis and reduction of protein C may have shifted the hemostatic balance towards coagulation. coincident with hyperbilirubinemia and other clinical signs of VOD, an approximately 10-fold rise in PAI-1 levels Determination of PIIINP levels in adult patients with hepatic complications other than VOD are necessary to was noted.
Although endothelial cell changes caused by toxicity of investigate its possible significance as a useful parameter for differentiating VOD from graft-versus-host disease, myeloablative chemotherapy are held mainly responsible for the development of VOD (for review see Ref. 1), other infections or toxic effects. Our results confirm the significance of PAI-1 as a marker additional factors seem to have contributed to the late onset of VOD in patient 1. Our patient had evidence of pneuof veno-occlusive disease, although its sensitivity is limited in patients with severe sepsis and septic shock. monia and CMV viremia on readmission, both of which may be responsible for inflammatory 'signals' resulting in additional endothelial cell activation.
Although we cannot completely rule out a contribution (unpublished results) and has previously been described by 
